Radiopharmaceutical CDMO Market Size & Trends Report Segmented by Type (Technetium-99m, Fluorine-18, Leutetium-177, Gallium-68, Actinium-225), Application (Diagnostic, Therapeutic), Phase (Pre-clinical, Clinical, Commercial), Indication (Cardiology, Oncology, Neurology) & Regional Forecasts to 2030
The global radiopharmaceutical CDMO market is set to witness a growth rate of ~9% in the next 5 years. High manufacturing costs and infrastructure investment, complexity and time sensitivity of manufacturing, advancements in nuclear medicine, and increasing outsourcing to reduce costs and accelerate time-to-market are some of the key factors driving the radiopharmaceutical CDMO market. To learn more about the research report, download a sample report.
Overview
A radiopharmaceutical contract development and manufacturing organization (CDMO) is a specialized service provider that manages the end-to-end development, manufacturing, and regulatory compliance for radiopharmaceutical drugs. These organizations possess advanced facilities and expertise to handle the production of radioactive compounds used in nuclear medicine for diagnostic imaging and targeted therapies. They offer comprehensive support ranging from process optimization and analytical development to large-scale commercial manufacturing. Radiopharmaceutical CDMOs enable pharmaceutical companies to reduce capital investment, mitigate risk, and accelerate time-to-market by leveraging specialized knowledge and infrastructure, ensuring that high-quality, safe radiopharmaceutical products are consistently produced in compliance with strict regulatory standards.
To learn more about this report, download the PDF brochure
Complexity and time sensitivity of manufacturing to propel market demand
Radiopharmaceutical manufacturing is inherently complex due to the extremely short half-lives of radioactive isotopes and the critical need for extremely precise timing in production and delivery. The rapid decay of these isotopes demands strict adherence to accelerated processes, ensuring drugs reach patients before significant loss of activity occurs. This complexity requires specialized equipment, stringent quality control, and robust logistics, making in-house production both costly and challenging. Consequently, pharmaceutical companies increasingly rely on radiopharmaceutical CDMOs, which offer advanced facilities and expertise to efficiently manage time-sensitive manufacturing, ensuring consistent product quality and regulatory compliance while reducing overall risk and capital investment.
Advancements in nuclear medicine are driving the market growth
Advancements in nuclear medicine are fueling breakthroughs in diagnostic imaging and targeted therapies. Innovations in PET, SPECT, and molecular imaging enable earlier and more precise disease detection. These developments have led to the creation of novel radiopharmaceutical compounds that require complex, time-sensitive manufacturing processes. As a result, pharmaceutical companies increasingly depend on specialized radiopharmaceutical CDMOs to overcome production challenges, ensure consistent quality, and comply with rigorous regulatory standards. Growing research investments accelerate innovation, making CDMOs critical in translating cutting-edge discoveries into effective clinical solutions, ultimately reducing time-to-market and expanding the global impact of nuclear medicine therapies.
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global radiopharmaceutical CDMO market is marked by the presence of established and emerging market players such as Cardinal Health, Eckert & Ziegler, NorthStar Medical Radioisotopes, Nucleus RadioPharma, PharmaLogic, DuchemBio, Co., Ltd., Minerva Imaging, AtomVie, Eczacıbaşı-Monrol, and Seibersdorf Labor GmbH; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 - 2030 |
| Growth Rate | ~9% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Radiopharmaceutical Type, Application, Phase, Indication |
| Regional Scope |
|
| Key Companies Mapped | Cardinal Health, Eckert & Ziegler, NorthStar Medical Radioisotopes, Nucleus RadioPharma, PharmaLogic, DuchemBio, Co., Ltd., Minerva Imaging, AtomVie, Eczacıbaşı-Monrol, and Seibersdorf Labor GmbH among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Radiopharmaceutical CDMO Market Segmentation
This report by Medi-Tech Insights provides the size of the global radiopharmaceutical CDMO market at the regional- and country-level from 2023 to 2030. The report further segments the market based on radiopharmaceutical type, application, phase, and indication.
Market Size & Forecast (2023-2030), By Radiopharmaceutical Type, USD Million
- Technetium-99m
- Fluorine-18
- Leutetium-177
- Gallium-68
- Actinium-225
- Others
Market Size & Forecast (2023-2030), By Application, USD Million
- Diagnostic Radiopharmaceuticals
- PET Radiopharmaceuticals
- SPECT Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
- Alpha Emitters
- Beta Emitters
- Other Therapeutic Radiopharmaceuticals
Market Size & Forecast (2023-2030), By Phase, USD Million
- Pre-clinical
- Clinical
- Commercial
Market Size & Forecast (2023-2030), By Indication, USD Million
- Oncology
- Cardiovascular Disorders
- Neurological Disorders
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the radiopharmaceutical CDMO market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the radiopharmaceutical CDMO market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Radiopharmaceutical CDMO Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- High manufacturing costs and infrastructure investment
- Complexity and time sensitivity of manufacturing
- Advancements in nuclear medicine
- Increasing outsourcing to reduce costs and accelerate time-to-market
- Restraints
- Regulatory and quality compliance challenges
- Supply chain and isotope availability issues
- Opportunities
- Expansion into emerging markets
- Technological innovations in manufacturing
- Strategic partnerships and end-to-end solutions
- Key Market Trends
- Investment in regional distribution networks to overcome logistical challenges
- Growing focus on theranostics and personalized treatments in oncology
- Unmet Market Needs
- Industry Speaks
- Drivers
- Market Dynamics
- Global Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), By Radiopharmaceutical Type, USD Million
- Introduction
- Technetium-99m
- Fluorine-18
- Leutetium-177
- Gallium-68
- Actinium-225
- Others
- Global Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), By Application, USD Million
- Introduction
- Diagnostic Radiopharmaceuticals
- PET Radiopharmaceuticals
- SPECT Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
- Alpha Emitters
- Beta Emitters
- Other Therapeutic Radiopharmaceuticals
- Global Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), By Phase, USD Million
- Introduction
- Pre-clinical
- Clinical
- Commercial
- Global Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), By Indication, USD Million
- Introduction
- Oncology
- Cardiovascular Disorders
- Neurological Disorders
- Others
- Global Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), By Country, USD Million
- US
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Canada
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- US
- Europe Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), By Country, USD Million
- UK
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Germany
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- France
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Italy
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Spain
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Rest of Europe
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- UK
- Asia Pacific (APAC) Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), By Country, USD Million
- China
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Japan
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- India
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- China
- Latin America (LATAM) Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Middle East & Africa (MEA) Radiopharmaceutical CDMO Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Radiopharmaceutical Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2025)
- New Service Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Cardinal Health
- Eckert & Ziegler
- NorthStar Medical Radioisotopes
- Nucleus RadioPharma
- PharmaLogic
- DuchemBio, Co., Ltd.
- Minerva Imaging
- AtomVie
- Eczacıbaşı-Monrol
- Seibersdorf Labor GmbH
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Pharmaceutical and Biotechnology Companies and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
Features of the Report
- Comprehensive Market Coverage
- Market Size and Forecast
- Geographic & Segment Deep Dives
- Strategic Insights & Competitive Landscape
- Timely & Updated Data
- Growth Indicators & Future Outlook
- Quick Turnaround on Queries
- Analyst Support
- Report Customization Available
- Reports in PDF & Excel
